Wednesday 02 April 2025
Internal Reference Number: FOI_8329
Date Request Received: 05/12/2024 00:00:00
Date Request Replied To: 07/01/2025 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 4 months (August to November 2024) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib • Nemolizumab | |
| Answer To Question 1: • Abrocitinib <5 • Acitretin 13 • Alitretinoin <5 • Azathioprine <5 • Baricitinib 0 • Ciclosporin 14 • Dupilumab 27 • Lebrikizumab <5 • Methotrexate 27 • Mycophenolate mofetil <5 • Pimecrolimus <5 • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only - <5 • Tacrolimus ointment 21 • Tralokinumab <5 • Upadacitinib <5 • Nemolizumab 0 | |
| Question Number 2: If possible, for the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • 6 months to 5 • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: Phototherapy (UVB or PUVA) - for Atopic Dermatitis only - all aged 18 and above, for all other treatments: • 6 months to 5 = 6 • Age 6-11 = 0 • Age 12-17 = <5 • Age 18 and above = 103 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
